PainReform (PRFX) Competitors $1.62 +0.22 (+15.25%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.56 -0.07 (-4.31%) As of 09/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. APM, TXMD, EPIX, ALVR, BFRG, GOVX, LGVN, GELS, LPTX, and BIVIShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Aptorum Group (APM), TherapeuticsMD (TXMD), ESSA Pharma (EPIX), AlloVir (ALVR), Bullfrog AI (BFRG), GeoVax Labs (GOVX), Longeveron (LGVN), Gelteq (GELS), Leap Therapeutics (LPTX), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors Aptorum Group TherapeuticsMD ESSA Pharma AlloVir Bullfrog AI GeoVax Labs Longeveron Gelteq Leap Therapeutics BioVie PainReform (NASDAQ:PRFX) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts prefer PRFX or APM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in PRFX or APM? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, PRFX or APM? PainReform has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Which has stronger valuation and earnings, PRFX or APM? Aptorum Group has higher revenue and earnings than PainReform. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01Aptorum Group$430K23.02-$4.27MN/AN/A Is PRFX or APM more profitable? Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A Aptorum Group N/A N/A N/A Does the media prefer PRFX or APM? In the previous week, Aptorum Group had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for Aptorum Group and 0 mentions for PainReform. Aptorum Group's average media sentiment score of 1.00 beat PainReform's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the news media. Company Overall Sentiment PainReform Neutral Aptorum Group Positive SummaryAptorum Group beats PainReform on 5 of the 8 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84M$2.55B$5.75B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.0122.9075.9926.43Price / SalesN/A714.55546.95119.09Price / CashN/A169.7737.0558.92Price / Book0.785.3910.916.06Net Income-$14.59M$32.95M$3.29B$266.28M7 Day Performance12.07%1.08%0.18%-0.32%1 Month Performance20.70%6.32%6.26%3.44%1 Year Performance95.97%-0.28%51.55%23.11% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform0.876 of 5 stars$1.63+15.2%N/A+88.9%$2.84MN/A-0.014APMAptorum Group2.2334 of 5 stars$2.47+5.9%N/A-39.3%$13.21MN/A0.0030Short Interest ↓Gap DownTXMDTherapeuticsMD0.2325 of 5 stars$1.13+1.8%N/A-38.6%$13.07M$1.76M0.00420EPIXESSA Pharma3.2493 of 5 stars$0.27-65.0%$2.00+629.9%-96.0%$13.01MN/A-0.4950Dividend AnnouncementGap DownHigh Trading VolumeALVRAlloVirN/A$2.51flatN/A-73.7%$12.66MN/A-0.12110BFRGBullfrog AI0.7686 of 5 stars$1.24+0.8%N/A-50.2%$12.50M$60K-1.634GOVXGeoVax Labs2.063 of 5 stars$0.78+3.2%$8.50+988.8%-80.8%$12.43M$6.14M-0.3910Gap UpLGVNLongeveron2.6271 of 5 stars$0.82+4.6%$7.25+789.6%-65.5%$12.37M$2.39M-0.1320Short Interest ↑GELSGelteqN/A$1.30-2.3%N/AN/A$12.27MN/A0.00N/ANews CoverageGap UpLPTXLeap Therapeutics1.6703 of 5 stars$0.30-4.8%$3.38+1,044.1%-90.3%$12.23MN/A-0.1940Gap DownBIVIBioVie0.3733 of 5 stars$1.61-2.7%N/A-94.0%$12.09MN/A-0.0210 Related Companies and Tools Related Companies APM Competitors TXMD Competitors EPIX Competitors ALVR Competitors BFRG Competitors GOVX Competitors LGVN Competitors GELS Competitors LPTX Competitors BIVI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
